The 1998 Workshop on Neuroimaging Research in Alzheimer's Disease: Observation and issues

M. J. De Leon, P. Scheltens, W. Jagust, G. Small, Charles DeCarli, L. O. Wahlund

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

In July of 1998, at the Amsterdam meeting of the International Alzheimer's Disease Congress, the first workshop was convened on the Neuroimaging of Alzheimer's Disease. Twenty-two of 24 presenters contributed to this document. Each contributor was asked to summarize a single salient observation on one of four topics: 1) Structural and functional brain imaging and dementia diagnosis; 2) assessment of Alzheimer's disease progression; 3) clinical and post-mortem validation studies; and 4) new and innovative imaging techniques. The summaries show that structural hippocampal formation (hippocampus and entorhinal cortex) changes are the most consistently observed early features of AD. SPECT perfusion studies and PET glucose metabolism studies, with arguably greater disease sensitivity, show the additional involvement of the temporal neocortical metabolism in the early stages of AD. It is offered that imaged changes could serve as biological indicators of disease progression. Progress continues to be made with the differential diagnosis of AD. Further, post mortem studies have been used increasingly to confirm diagnoses and provide anatomical validation for in vivo imaging of the hippocampus and entorhinal cortex. MRI spectroscopy, SPECT and PET studies promise the non-invasive longitudinal examination of brain chemistry and an expansion in the exploration for mechanisms of disease. We anticipate that the next few years will see the standardization of imaging protocols with the adoption of diagnostic imaging criteria for AD and with intervention studies using image derived outcome measures.

Original languageEnglish (US)
Pages (from-to)15-45
Number of pages31
JournalNeuroScience News
Volume3
Issue number5
StatePublished - 2000
Externally publishedYes

Fingerprint

Neuroimaging
Hippocampus
Entorhinal Cortex
Alzheimer Disease
Observation
Single-Photon Emission-Computed Tomography
Education
Disease Progression
Brain Chemistry
Research
Functional Neuroimaging
Validation Studies
Diagnostic Imaging
Dementia
Spectrum Analysis
Differential Diagnosis
Perfusion
Outcome Assessment (Health Care)
Glucose

Keywords

  • Alzheimer disease
  • CT
  • Diagnosis
  • MRI
  • Neuroimaging
  • PET
  • SPECT

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

De Leon, M. J., Scheltens, P., Jagust, W., Small, G., DeCarli, C., & Wahlund, L. O. (2000). The 1998 Workshop on Neuroimaging Research in Alzheimer's Disease: Observation and issues. NeuroScience News, 3(5), 15-45.

The 1998 Workshop on Neuroimaging Research in Alzheimer's Disease : Observation and issues. / De Leon, M. J.; Scheltens, P.; Jagust, W.; Small, G.; DeCarli, Charles; Wahlund, L. O.

In: NeuroScience News, Vol. 3, No. 5, 2000, p. 15-45.

Research output: Contribution to journalArticle

De Leon, MJ, Scheltens, P, Jagust, W, Small, G, DeCarli, C & Wahlund, LO 2000, 'The 1998 Workshop on Neuroimaging Research in Alzheimer's Disease: Observation and issues', NeuroScience News, vol. 3, no. 5, pp. 15-45.
De Leon, M. J. ; Scheltens, P. ; Jagust, W. ; Small, G. ; DeCarli, Charles ; Wahlund, L. O. / The 1998 Workshop on Neuroimaging Research in Alzheimer's Disease : Observation and issues. In: NeuroScience News. 2000 ; Vol. 3, No. 5. pp. 15-45.
@article{0d877c5975074d36a2befff39356af5c,
title = "The 1998 Workshop on Neuroimaging Research in Alzheimer's Disease: Observation and issues",
abstract = "In July of 1998, at the Amsterdam meeting of the International Alzheimer's Disease Congress, the first workshop was convened on the Neuroimaging of Alzheimer's Disease. Twenty-two of 24 presenters contributed to this document. Each contributor was asked to summarize a single salient observation on one of four topics: 1) Structural and functional brain imaging and dementia diagnosis; 2) assessment of Alzheimer's disease progression; 3) clinical and post-mortem validation studies; and 4) new and innovative imaging techniques. The summaries show that structural hippocampal formation (hippocampus and entorhinal cortex) changes are the most consistently observed early features of AD. SPECT perfusion studies and PET glucose metabolism studies, with arguably greater disease sensitivity, show the additional involvement of the temporal neocortical metabolism in the early stages of AD. It is offered that imaged changes could serve as biological indicators of disease progression. Progress continues to be made with the differential diagnosis of AD. Further, post mortem studies have been used increasingly to confirm diagnoses and provide anatomical validation for in vivo imaging of the hippocampus and entorhinal cortex. MRI spectroscopy, SPECT and PET studies promise the non-invasive longitudinal examination of brain chemistry and an expansion in the exploration for mechanisms of disease. We anticipate that the next few years will see the standardization of imaging protocols with the adoption of diagnostic imaging criteria for AD and with intervention studies using image derived outcome measures.",
keywords = "Alzheimer disease, CT, Diagnosis, MRI, Neuroimaging, PET, SPECT",
author = "{De Leon}, {M. J.} and P. Scheltens and W. Jagust and G. Small and Charles DeCarli and Wahlund, {L. O.}",
year = "2000",
language = "English (US)",
volume = "3",
pages = "15--45",
journal = "NeuroScience News",
issn = "1027-6599",
publisher = "G&B Magazines",
number = "5",

}

TY - JOUR

T1 - The 1998 Workshop on Neuroimaging Research in Alzheimer's Disease

T2 - Observation and issues

AU - De Leon, M. J.

AU - Scheltens, P.

AU - Jagust, W.

AU - Small, G.

AU - DeCarli, Charles

AU - Wahlund, L. O.

PY - 2000

Y1 - 2000

N2 - In July of 1998, at the Amsterdam meeting of the International Alzheimer's Disease Congress, the first workshop was convened on the Neuroimaging of Alzheimer's Disease. Twenty-two of 24 presenters contributed to this document. Each contributor was asked to summarize a single salient observation on one of four topics: 1) Structural and functional brain imaging and dementia diagnosis; 2) assessment of Alzheimer's disease progression; 3) clinical and post-mortem validation studies; and 4) new and innovative imaging techniques. The summaries show that structural hippocampal formation (hippocampus and entorhinal cortex) changes are the most consistently observed early features of AD. SPECT perfusion studies and PET glucose metabolism studies, with arguably greater disease sensitivity, show the additional involvement of the temporal neocortical metabolism in the early stages of AD. It is offered that imaged changes could serve as biological indicators of disease progression. Progress continues to be made with the differential diagnosis of AD. Further, post mortem studies have been used increasingly to confirm diagnoses and provide anatomical validation for in vivo imaging of the hippocampus and entorhinal cortex. MRI spectroscopy, SPECT and PET studies promise the non-invasive longitudinal examination of brain chemistry and an expansion in the exploration for mechanisms of disease. We anticipate that the next few years will see the standardization of imaging protocols with the adoption of diagnostic imaging criteria for AD and with intervention studies using image derived outcome measures.

AB - In July of 1998, at the Amsterdam meeting of the International Alzheimer's Disease Congress, the first workshop was convened on the Neuroimaging of Alzheimer's Disease. Twenty-two of 24 presenters contributed to this document. Each contributor was asked to summarize a single salient observation on one of four topics: 1) Structural and functional brain imaging and dementia diagnosis; 2) assessment of Alzheimer's disease progression; 3) clinical and post-mortem validation studies; and 4) new and innovative imaging techniques. The summaries show that structural hippocampal formation (hippocampus and entorhinal cortex) changes are the most consistently observed early features of AD. SPECT perfusion studies and PET glucose metabolism studies, with arguably greater disease sensitivity, show the additional involvement of the temporal neocortical metabolism in the early stages of AD. It is offered that imaged changes could serve as biological indicators of disease progression. Progress continues to be made with the differential diagnosis of AD. Further, post mortem studies have been used increasingly to confirm diagnoses and provide anatomical validation for in vivo imaging of the hippocampus and entorhinal cortex. MRI spectroscopy, SPECT and PET studies promise the non-invasive longitudinal examination of brain chemistry and an expansion in the exploration for mechanisms of disease. We anticipate that the next few years will see the standardization of imaging protocols with the adoption of diagnostic imaging criteria for AD and with intervention studies using image derived outcome measures.

KW - Alzheimer disease

KW - CT

KW - Diagnosis

KW - MRI

KW - Neuroimaging

KW - PET

KW - SPECT

UR - http://www.scopus.com/inward/record.url?scp=0033748010&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033748010&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0033748010

VL - 3

SP - 15

EP - 45

JO - NeuroScience News

JF - NeuroScience News

SN - 1027-6599

IS - 5

ER -